Search: id:"swepub:oai:DiVA.org:su-121661" >
A fusion protein de...
-
Mukherjee, OindrillaLund University,Lunds universitet,Klinisk mikrobiologi, Malmö,Forskargrupper vid Lunds universitet,Clinical Microbiology, Malmö,Lund University Research Groups
(author)
A fusion protein derived from Moraxella catarrhalis and Neisseria meningitidis aimed for immune modulation of human B cells
- Article/chapterEnglish2015
Publisher, publication year, extent ...
-
2015-06-04
-
Informa UK Limited,2015
-
printrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:su-121661
-
https://urn.kb.se/resolve?urn=urn:nbn:se:su:diva-121661URI
-
https://doi.org/10.1080/21645515.2015.1034917DOI
-
https://lup.lub.lu.se/record/7488240URI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
Moraxella IgD-binding protein (MID) is a well characterized trimeric autotransporter that specifically targets the IgD of B cells. We fused the membrane anchor of the meningococcal autotransporter NhhA with the IgD-binding region of MID (aa 962-1200) to create a chimeric protein designated as NID. The aim was to use this specific targeting to provide a better vaccine candidate against meningococci, in particular serogroup B by enhancing the immunogenicity of NhhA. NID was thereafter recombinantly expressed in E. coli. The NID-expressing E. coli bound to peripheral B lymphocytes that resulted in cellular activation. Furthermore, we also successfully expressed NID on outer membrane vesicles, nanoparticles that are commonly used in meningococcal vaccines. This study thus highlights the applicability of the menigococcal-Moraxella fusion protein NID to be used for specific targeting of vaccine components to the IgD B cell receptor.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Singh, BirendraLund University,Lunds universitet,Klinisk mikrobiologi, Malmö,Forskargrupper vid Lunds universitet,Clinical Microbiology, Malmö,Lund University Research Groups(Swepub:lu)med-bas
(author)
-
Bayrak, BurcuLund University,Lunds universitet,Klinisk mikrobiologi, Malmö,Forskargrupper vid Lunds universitet,Clinical Microbiology, Malmö,Lund University Research Groups(Swepub:lu)med-bbk
(author)
-
Jonsson, Ann-BethStockholms universitet,Institutionen för molekylär biovetenskap, Wenner-Grens institut(Swepub:su)anjons
(author)
-
Mörgelin, MatthiasLund University,Lunds universitet,Infektionsmedicin,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Infection Medicine (BMC),Section III,Department of Clinical Sciences, Lund,Faculty of Medicine(Swepub:lu)medk-mmn
(author)
-
Riesbeck, KristianLund University,Lunds universitet,Klinisk mikrobiologi, Malmö,Forskargrupper vid Lunds universitet,Clinical Microbiology, Malmö,Lund University Research Groups(Swepub:lu)mikr-kri
(author)
-
Klinisk mikrobiologi, MalmöForskargrupper vid Lunds universitet
(creator_code:org_t)
Related titles
-
In:Human Vaccines & Immunotherapeutics: Informa UK Limited11:9, s. 2223-22272164-55152164-554X
Internet link
Find in a library
To the university's database